Compare PRT & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRT | PDSB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 29.6M |
| IPO Year | N/A | 2015 |
| Metric | PRT | PDSB |
|---|---|---|
| Price | $2.25 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 85.1K | ★ 982.6K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $0.51 |
| 52 Week High | $4.28 | $1.90 |
| Indicator | PRT | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 17.53 | 48.29 |
| Support Level | N/A | $0.85 |
| Resistance Level | $3.62 | $1.12 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 4.35 | 17.69 |
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.